NCT02317796 - Adult Subjects With Uncontrolled Type 2 Diabetes | Biotech Hunter

Enrollment

149

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

February 29, 2016

Conditions

Type 2 Diabetes

Interventions

DRUG

MLR-1023

Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.

Trial Locations (1)

Unknown

Melior Pharmaceuticals I & Bukwang Pharm. Co., Ltd., USA and South Korea